Fig. 2.

Best response to second-line targeted therapy grouped by initial best response to first-line targeted therapy. Abbreviations: CR1 complete response to first-line VEGF-targeted therapy, PR1 partial response to first-line VEGF-targeted therapy, SD1 stable disease to first-line VEGF-targeted therapy, PD1 progressive disease to first-line VEGF-targeted therapy, CR2 complete response to second-line VEGF-targeted therapy, PR2 partial response to second-line VEGF-targeted therapy, SD2 stable disease to second-line VEGF-targeted therapy, PD2 progressive disease to second-line VEGF-targeted therapy